"Professional guinea pigs": Inside the world of clinical drug trials
Podcast |
The Big Story
Media Type |
audio
Categories Via RSS |
Daily News
News
News Commentary
Politics
Publication Date |
Oct 07, 2024
Episode Duration |
00:23:47

Being a part of a clinical drug trial can pay very well—up to several thousand dollars. And a lot of people need that cash and are desperate to take part. 

But when someone's desperate for that money, they'll cut a lot of corners: lie to be accepted, fail to report adverse reactions or other complicating factors and skip the mandatory recovery time between trials. When that happens, it can throw everything off, including the data that Health Canada may be relying on in order to approve these drugs for all of us to use...

GUEST: Rob Cribb, director of the Investigative Journalism Bureau, investigative reporter at the Toronto Star

We love feedback at The Big Story, as well as suggestions for future episodes. You can find us:

Through email at hello@thebigstorypodcast.ca 

Or by calling 416-935-5935 and leaving us a voicemail

Or @thebigstoryfpn on Twitter

Being a part of a clinical drug trial can pay very well—up to several thousand dollars. And a lot of people need that cash and are desperate to take part. But when someone's desperate for that money, they'll cut a lot of corners: lie to be accepted, fail to report adverse reactions or other complicating factors and skip the mandatory recovery time between trials. When that happens, it can throw everything off, including the data that Health Canada may be relying on in order to approve these drugs for all of us to use... GUEST: Rob Cribb, director of the Investigative Journalism Bureau, investigative reporter at the Toronto Star

Being a part of a clinical drug trial can pay very well—up to several thousand dollars. And a lot of people need that cash and are desperate to take part. 

But when someone's desperate for that money, they'll cut a lot of corners: lie to be accepted, fail to report adverse reactions or other complicating factors and skip the mandatory recovery time between trials. When that happens, it can throw everything off, including the data that Health Canada may be relying on in order to approve these drugs for all of us to use...

GUEST: Rob Cribb, director of the Investigative Journalism Bureau, investigative reporter at the Toronto Star

We love feedback at The Big Story, as well as suggestions for future episodes. You can find us:

Through email at hello@thebigstorypodcast.ca 

Or by calling 416-935-5935 and leaving us a voicemail

Or @thebigstoryfpn on Twitter

This episode currently has no reviews.

Submit Review
This episode could use a review!

This episode could use a review! Have anything to say about it? Share your thoughts using the button below.

Submit Review